India’s CDMO Sector Set to Boom as Global Pharma Diversifies from China

The global pharmaceutical landscape is undergoing a massive structural realignment as multinational companies look to reduce their dependence on China. Indian Contract Development and Manufacturing Organisations (CDMOs) are emerging as the primary beneficiaries of this "China Plus One" strategy, positioning the nation as a trusted hub for drug manufacturing.

The Shift from China to India

The transition away from Chinese manufacturing is no longer a theoretical possibility but an active reality. According to Sivaramakrishnan Chittor, CFO of Sai Life Sciences, the genesis of this shift began nearly two years ago, well before recent heightened regulatory scrutiny regarding Chinese giants like WuXi AppTec.

The inclusion of specific regulatory lists has further cleared the path for global pharma companies to diversify their supply chains. As these companies seek to mitigate geopolitical and regulatory risks, India has become their "best bet." Leading Indian players are already responding by scaling up operations and increasing capital expenditure (capex) to meet this surging global demand.

Sai Life Sciences: Scaling for a Global Market

Sai Life Sciences is actively positioning itself to capture this windfall. The company has announced a significant capacity expansion plan, aiming to invest between ₹1,100 crore and ₹1,300 crore by FY27. This expansion will be funded through a combination of internal accruals and debt, maintaining a healthy balance sheet.

A key indicator of this successful shift is the company's revenue mix. Over the last four years, the contribution from global large pharmaceutical companies has nearly doubled, rising from 28% to 49% of total revenue. This reflects a deeper integration of Indian CDMOs into the long-term value chains of the world's largest drugmakers.

From Clinical Supplies to Commercial Manufacturing

One of the most significant trends in the industry is the evolving role of India in the drug development lifecycle. Historically, many global pharmaceutical firms utilized Indian CDMOs primarily for clinical trial supplies. However, there is now a decisive move toward using India for large-scale commercial manufacturing.

Sai Life Sciences has noted a substantial increase in its late-stage development pipeline. The number of Phase III and pre-registration molecules has grown from six to eleven over the past year. This uptick in Phase III molecules serves as a fundamental signal that global innovators now view Indian facilities as capable of handling high-volume, commercial-scale production.

Growth Outlook and Regulatory Realities

While the opportunity is immense, experts caution that the transition will not happen overnight. Because pharmaceutical manufacturing is heavily regulated, moving a product from one manufacturer to another requires rigorous regulatory approvals and lengthy product transfer timelines.

Consequently, Sai Life Sciences has maintained a steady revenue growth guidance of 15-20% CAGR. While the full impact of the China diversification may not manifest in immediate quarterly results, the long-term structural shift provides a robust runway for growth through the end of the decade.

Key Takeaways

• Strategic Diversification: Global pharmaceutical companies are actively moving manufacturing footprints away from China to mitigate regulatory risks, favoring India as a primary alternative.
• Capacity Expansion: Major Indian players like Sai Life Sciences are investing up to ₹1,300 crore to scale capacity, aiming to meet the demand for both clinical and commercial-scale manufacturing.
• Shift in Value Chain: India is moving up the value chain, transitioning from a provider of clinical trial supplies to a trusted partner for large-scale commercial drug production.